Researchers have reported the first clinical evidence that drug-resistant mutations of the parasite responsible for malaria are gaining ground in Africa. Experts have long worried about the emergence of drug resistance across the continent, which accounted for more than 90 percent of malaria deaths worldwide in 2019. A new study published in The Lancet on Thursday appears to confirm those fears. In clinical trials, the disease lingered longer in children receiving standard treatment for malaria if they were infected with mutant strains of the disease, the study found. The efficacy of artemisinin-based combination therapies (ACTs) remained high, but the researchers said there was an “urgent need” for more monitoring in Rwanda, where the study was conducted, as well as in neighbouring countries. “Our study shows that resistant isolates are starting to become more common,” said lead author Aline Uwimana, a researcher at the Rwanda Biomedical Centre in Kigali.
SOURCE: AL JAZEERA
More Stories
African and Global Firms Contribute towards Harris’ Empowerment Fund
The Main Winners in Nigeria’s Botched Currency Overhaul are Two Chinese-owned Fintech Apps
The Growing Opportunities that African Pharmaceuticals Present
Africa’s Extraction and Export of Raw Materials is Rising
Accra’s Plan on a Debt-free Life
Mauto is Preparing Benin—and Africa—for an e-bike Ride
Rwanda’s Long History of Mining
Disease Stops Trade in East Africa’s Border Towns
A Marketplace for Medical Equipment in Addis
South African Rate Hike Exceeds All Expectations
At the Coalface of the Green Revolution, but Earning Crumbs
Harris Stresses that U.S. Interests in African Nations Extends beyond Competing with China